βeta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trial
Study context
- Population
- Patients with prior (>6 months) myocardial infarction (MI), left ventricular ejection fraction (LVEF) >40%, chronically treated with a β-blocker, without major cardiovascular event (MACE) in the past 6 monthsenrolment completed
- Participants
- 3,700 patients
- Planned comparison
- β-blocker interruption vs continuation
- Primary endpoint
- Composite of:
- All-cause death
- Stroke
- MI
- Hospitalisation for any CV reason (non-inferiority of interruption vs continuation)
- Follow-up
- End (accrual ), minimum 1 year for last randomised patient
Methodological detailsrationale and design, non-inferiority, multicentre, 49 centres in France, Secondary objectives: patient-reported outcomes, quality of life before and after randomisation (EQ5D-5L)
- Rationale and design
- Non-inferiority
- Multicentre
- 49 centres in France
- Secondary objectives: patient-reported outcomes, quality of life before and after randomisation (EQ5D-5L)
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
βeta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trial. Am Heart J. Published 20 January 2023. doi:10.
Summarised from the published abstract; every number is checked against it